ResearchNVCR

NVCR: FY25 Deep Dive

Ddrillr ResearchOriginal research

Published Sep 3, 20261 min read

Summary

NovoCure FY25 at $655M. NI $-136M; EPS $-1.22.

FY25 revenue $655M; OI $-154M; NI $-136M; EPS $-1.22.

NovoCure FY25 (Dec 31, 2025) at $655M revenue. OpInc $-154M; NI $-136M; EPS $-1.22. Medical Devices — Oncology.